Prolonged delivery of HIV-1 vaccine nanoparticles from hydrogels.

Antigen PEGylation Co-delivery Env HIV vaccine PEG hydrogel Silica nanoparticles Sustained release

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
19 Apr 2024
Historique:
received: 13 02 2024
revised: 14 04 2024
accepted: 15 04 2024
medline: 22 4 2024
pubmed: 22 4 2024
entrez: 21 4 2024
Statut: aheadofprint

Résumé

Immunization is a straightforward concept but remains for some pathogens like HIV-1 a challenge. Thus, new approaches towards increasing the efficacy of vaccines are required to turn the tide. There is increasing evidence that antigen exposure over several days to weeks induces a much stronger and more sustained immune response compared to traditional bolus injection, which usually leads to antigen elimination from the body within a couple of days. Therefore, we developed a poly(ethylene) glycol (PEG) hydrogel platform to investigate the principal feasibility of a sustained release of antigens to mimic natural infection kinetics. Eight-and four-armed PEG macromonomers of different MWs (10, 20, and 40 kDa) were end-group functionalized to allow for hydrogel formation via covalent cross-linking. An HIV-1 envelope (Env) antigen in its trimeric (Env

Identifiants

pubmed: 38643811
pii: S0378-5173(24)00365-X
doi: 10.1016/j.ijpharm.2024.124131
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124131

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Raphael Mietzner (R)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany.

Clara Barbey (C)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany.

Heike Lehr (H)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany.

Christian E Ziegler (CE)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany.

David Peterhoff (D)

Institute of Medical Microbiology and Hygiene, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

Ralf Wagner (R)

Institute of Medical Microbiology and Hygiene, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

Achim Goepferich (A)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany.

Miriam Breunig (M)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93040 Regensburg, Germany. Electronic address: miriam.breunig@ur.de.

Classifications MeSH